{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":9,"podcast":5,"x_thread":5},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05050097\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MonumenTAL-2","nct_id":"NCT05050097","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=monumental-2-nct05050097. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MonumenTAL-2","arms":[{"description":"Participants assigned to Treatment regimen A will receive talquetamab subcutaneously (SC) in combination with carfilzomib as an intravenous (IV) infusion.","label":"Treatment Regimen A: Talquetamab + Carfilzomib","type":"EXPERIMENTAL"},{"description":"Participants assigned to Treatment regimen B will receive talquetamab SC in combination with daratumumab SC and carfilzomib as an IV infusion.","label":"Treatment Regimen B: Talquetamab + Daratumumab + Carfilzomib","type":"EXPERIMENTAL"},{"description":"Participants assigned to Treatment regimen C will receive talquetamab SC in combination with lenalidomide orally.","label":"Treatment Regimen C: Talquetamab + Lenalidomide","type":"EXPERIMENTAL"},{"description":"Participants assigned to Treatment regimen D will receive talquetamab SC in combination with daratumumab SC and lenalidomide orally.","label":"Treatment Regimen D: Talquetamab + Daratumumab + Lenalidomide","type":"EXPERIMENTAL"},{"description":"Participants assigned to Treatment regimen E will receive talquetamab SC in combination with pomalidomide orally.","label":"Treatment Regimen E: Talquetamab + Pomalidomide","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2027-12-31","type":"ESTIMATED"},"conditions":["Multiple Myeloma"],"enrollment":{"count":166,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Talquetamab","type":"DRUG"},{"name":"Carfilzomib","type":"DRUG"},{"name":"Daratumumab SC","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Pomalidomide","type":"DRUG"}],"last_update":"2026-09-28","lead_sponsor":"Janssen Research & Development, LLC","official_title":"A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1"],"primary_completion_date":{"date":"2025-03-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Number of Participants with Adverse Events (AEs) as a Measure of Safety and Tolerability","timeFrame":"Up to 1 year and 10 months"},{"measure":"Number of Participants with AEs by Severity","timeFrame":"Up to 1 year and 10 months"},{"measure":"Number of Participants with Clinically Significant Abnormalities in Laboratory Parameters","timeFrame":"Up to 1 year and 6 months"},{"measure":"Number of Participants with Dose Limiting Toxicity (DLT)","timeFrame":"Up to 49 days"}],"references":[],"start_date":{"date":"2021-09-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma","url":"https://clinicaltrials.gov/study/NCT05050097"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/monumental-2-nct05050097"}